Valuation
- Market cap
- 4,315,343,000
- Revenue TTM
- $2,040,000
- Net income TTM
- $-162,340,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -7,957.84%
- Debt to equity
- 0.00
Trading
- Volume
- 599,377
- Avg volume
- 829,830
- Day's range
- $75.40 – $78.96
- Shares out
- 54,798,000
- Stochastic %K
- 55%
- Beta
- 1.35
- Analysts
- Strong Sell
- Price target
- $140.12
Company profile
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendri...
Show more
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 929 999 4055
- Website
- https://dianthustx.com
- Address
- 7 Times Square, 43rd Floor, New York, United States
Latest news
No headlines yet.
